Trial · NCT07579598
ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma
NCT07579598, Phase 2, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma. Trials, record NCT07579598. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07579598
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma
- NCT number
- NCT07579598
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Conditions
- Adenoid Cystic Carcinoma of the Head and Neck, SBRT, Antibody-drug Conjugates
- Interventions
- Becotatug Vedotin, SBRT, Becotatug Vedotin or Sacituzumab Tirumotecan
- First posted
- 2026-05-12
- Last updated
- 2026-05-12
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | 1-year | the proportion of patients with a reduction in tumor volume of a predefined amount and for a minimum time period, including complete response (CR) and partial response (PR) cases |
| Secondary | Time to Response (TTR) | 1-year | the interval from the date of treatmentinitiation (typically the first dose) to the date of the firstdocumented objective response (complete response \[CR\] or partial response \[PR\]). * TTR1 (Onset of response to ADC): Defined as the time from initiationof antibody-drug conjugate (ADC) therapy to the first occurrence of an objective response(PR or CR). This metric reflects the initial onset of action of the ADC, whether administeredas monotherapy or as part of a combination regimen. * TTR2(Onset of response to the overall combination therapy): Defined as the time from initiation of the fullcombination treatment regimen (i.e., after receivingADC therapy and completing the first course of SBRT) to the first occurrence of an objective response. This endpoint evaluates the onset of efficacy ofthe combination therapy as an integrated treatment approach. |
| Secondary | Disease Disease Control Rate (DCR) | 1-year | Proportion of patients with a best overall response of confirmed CR, PR, or SD (SD must be confirmed at least 4 weeks after initial documentation). |
| Secondary | Progression-Free Survival (PFS) | 1-year | Time from first treatment to disease progression or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | 1-year | Time from first treatment to death from any cause. |
| Secondary | Duration of Response (DOR) | 1-year | Time from first documented objective response to disease progression or death, in patients with a confirmed objective response. |
| Secondary | Adverse Events (AEs) | 2-year | Including type, incidence, severity (graded per NCI-CTCAE v5.0), duration, and relationship to study drugs. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07579598
GET https://conductscience.org/api/trials/v1/NCT07579598/registered